166 related articles for article (PubMed ID: 34634936)
1. Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity.
Goldberg BS; Kaku CI; Dufloo J; Bruel T; Schwartz O; Spencer DA; Hessell AJ; Ackerman ME
mBio; 2021 Oct; 12(5):e0174321. PubMed ID: 34634936
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
3. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
[TBL] [Abstract][Full Text] [Related]
4. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
[TBL] [Abstract][Full Text] [Related]
5. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.
Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L
PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection.
Muenchhoff M; Chung AW; Roider J; Dugast AS; Richardson S; Kløverpris H; Leslie A; Ndung'u T; Moore P; Alter G; Goulder PJR
mSphere; 2020 Dec; 5(6):. PubMed ID: 33361123
[TBL] [Abstract][Full Text] [Related]
7. Complement contributes to antibody-mediated protection against repeated SHIV challenge.
Goldberg BS; Spencer DA; Pandey S; Ordonez T; Barnette P; Yu Y; Gao L; Dufloo J; Bruel T; Schwartz O; Ackerman ME; Hessell AJ
Proc Natl Acad Sci U S A; 2023 May; 120(20):e2221247120. PubMed ID: 37155897
[TBL] [Abstract][Full Text] [Related]
8. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
[TBL] [Abstract][Full Text] [Related]
10. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
11. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
12. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
Parsons MS; Chung AW; Kent SJ
Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
15. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis.
Spencer DA; Goldberg BS; Pandey S; Ordonez T; Dufloo J; Barnette P; Sutton WF; Henderson H; Agnor R; Gao L; Bruel T; Schwartz O; Haigwood NL; Ackerman ME; Hessell AJ
Nat Commun; 2022 Feb; 13(1):662. PubMed ID: 35115533
[TBL] [Abstract][Full Text] [Related]
16. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
[TBL] [Abstract][Full Text] [Related]
17. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
18. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
19. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
Rudicell RS; Kwon YD; Ko SY; Pegu A; Louder MK; Georgiev IS; Wu X; Zhu J; Boyington JC; Chen X; Shi W; Yang ZY; Doria-Rose NA; McKee K; O'Dell S; Schmidt SD; Chuang GY; Druz A; Soto C; Yang Y; Zhang B; Zhou T; Todd JP; Lloyd KE; Eudailey J; Roberts KE; Donald BR; Bailer RT; Ledgerwood J; ; Mullikin JC; Shapiro L; Koup RA; Graham BS; Nason MC; Connors M; Haynes BF; Rao SS; Roederer M; Kwong PD; Mascola JR; Nabel GJ
J Virol; 2014 Nov; 88(21):12669-82. PubMed ID: 25142607
[TBL] [Abstract][Full Text] [Related]
20. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]